Department of Cardiology, Changi General Hospital; Ministry of Health Holdings Pte Ltd, Singapore.
Department of Cardiology, Changi General Hospital, Singapore.
Singapore Med J. 2023 Jun;64(6):373-378. doi: 10.11622/smedj.2022066.
Despite the challenges related to His bundle pacing (HBP), recent data suggest an improved success rate with experience. As a non-university, non-electrophysiology specialised centre in Singapore, we report our experiences in HBP using pacing system analyser alone.
Data of 28 consecutive patients who underwent HBP from August 2018 to February 2019 was retrospectively obtained. The clinical and technical outcomes of these patients were compared between two timeframes of three months each. Patients were followed up for 12 months.
Immediate technical success was achieved in 21 (75.0%) patients (mean age 73.3 ± 10.7 years, 47.6% female). The mean left ventricular ejection fraction was 53.9% ± 12.1%. The indications for HBP were atrioventricular block (n = 13, 61.9%), sinus node dysfunction (n = 7, 33.3%) and upgrade from implantable cardioverter-defibrillator to His-cardiac resynchronisation therapy (n = 1, 4.8%). No significant difference was observed in baseline characteristics between Timeframe 1 and Timeframe 2. Improvements pertaining to mean fluoroscopy time were achieved between the two timeframes. There was one HBP-related complication of lead displacement during Timeframe 1. All patients with successful HBP achieved non-selective His bundle (NSHB) capture, whereas only eight patients had selective His bundle (SHB) capture. NSHB and SHB capture thresholds remained stable at the 12-month follow-up.
Permanent HBP is feasible and safe, even without the use of an electrophysiology recording system. This was successfully achieved in 75% of patients, with no adverse clinical outcomes during the follow-up period.
尽管存在与希氏束起搏(HBP)相关的挑战,但最近的数据表明,随着经验的积累,成功率有所提高。作为新加坡的一家非大学、非电生理专科中心,我们仅使用起搏系统分析仪报告了我们在 HBP 方面的经验。
回顾性获取了 2018 年 8 月至 2019 年 2 月期间连续 28 例接受 HBP 的患者的数据。比较了这两组患者在每个时间段(各持续 3 个月)的临床和技术结果。对患者进行了 12 个月的随访。
21 例(75.0%)患者即刻技术成功(平均年龄 73.3 ± 10.7 岁,47.6%为女性)。左心室射血分数平均为 53.9% ± 12.1%。HBP 的适应证为房室传导阻滞(n = 13,61.9%)、窦房结功能障碍(n = 7,33.3%)和从植入式心脏复律除颤器升级为希氏心脏再同步治疗(n = 1,4.8%)。时间段 1 和时间段 2 之间的基线特征无显著差异。两个时间段之间,平均透视时间有所改善。在时间段 1 期间发生了 1 例与 HBP 相关的导线移位并发症。所有成功进行 HBP 的患者均实现了非选择性希氏束(NSHB)捕获,而仅有 8 例患者实现了选择性希氏束(SHB)捕获。NSHB 和 SHB 捕获阈值在 12 个月随访时保持稳定。
即使不使用电生理记录系统,永久性 HBP 也是可行且安全的。在这项研究中,75%的患者成功实现了永久性 HBP,且在随访期间无不良临床结果。